<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1702">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05561205</url>
  </required_header>
  <id_info>
    <org_study_id>SUN-5342</org_study_id>
    <nct_id>NCT05561205</nct_id>
  </id_info>
  <brief_title>rTMS for Apathy Clinical Trial</brief_title>
  <acronym>REACT</acronym>
  <official_title>Repetitive Transcranial Magnetic Stimulation for Apathy Clinical Trial (REACT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apathy is a common, early, and disabling symptom in dementias such as Alzheimer's disease&#xD;
      (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial&#xD;
      magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a&#xD;
      medication, have been shown to improve apathy. This pilot study will investigate rTMS as a&#xD;
      treatment for apathy in AD in individuals receiving methylphenidate and individuals not&#xD;
      receiving medication for apathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2022</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apathy Evaluation Scale</measure>
    <time_frame>2 weeks</time_frame>
    <description>Measure of apathy on a scale from 18 to 72 with a lower score indicating greater apathy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Apathy in Dementia</condition>
  <arm_group>
    <arm_group_label>rTMS + methylphenidate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>repetitive transcranial magnetic stimulation (rTMS) and methylphenidate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rTMS only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>repetitive transcranial magnetic stimulation (rTMS) only</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>rTMS</intervention_name>
    <description>repetitive transcranial magnetic stimulation</description>
    <arm_group_label>rTMS + methylphenidate</arm_group_label>
    <arm_group_label>rTMS only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylphenidate</intervention_name>
    <description>methylphenidate</description>
    <arm_group_label>rTMS + methylphenidate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Alzheimer's disease or mixed Alzheimer's disease/vascular disease&#xD;
&#xD;
          -  Apathy for at least 4 weeks&#xD;
&#xD;
          -  Stable dose of medication (&gt;4 weeks) that may affect cognition or behaviour&#xD;
&#xD;
          -  Care partner who spends at least 10 hours a week with the subject&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current major depressive episode&#xD;
&#xD;
          -  Agitation, delusions, hallucination&#xD;
&#xD;
          -  Medical contraindications to rTMS&#xD;
&#xD;
          -  Currently taking an amphetamine product&#xD;
&#xD;
          -  Central nervous system abnormalities, Tourette's syndrome, or motor tics&#xD;
&#xD;
          -  Current participation in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krushnaa Sankhe</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>63095</phone_ext>
      <email>krushnaa.sankhe@sri.utoronto.ca</email>
    </contact>
    <investigator>
      <last_name>Krista L Lanct√¥t, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>September 27, 2022</study_first_submitted>
  <study_first_submitted_qc>September 29, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2022</study_first_posted>
  <last_update_submitted>September 29, 2022</last_update_submitted>
  <last_update_submitted_qc>September 29, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Apathy</keyword>
  <keyword>Alzheimer's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

